Supplementary Table 5 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Authors:

Abstract
Supplemental Table S5. Adverse events ({greater than or equal to} 15% incidence of all grades events in any of the patient treatment arms)